Grid-Shaped Radiation Beats Conventional Beams in Boosting CAR T Therapy for Brain Lymphoma

Primary central nervous system lymphoma is among the most feared diagnoses in neuro-oncology. The aggressive B-cell tumor arises exclusively within the brain and surrounding nervous tissue, and although high-dose methotrexate-based chemotherapy followed by whole-brain radiotherapy can produce impressive initial responses, the price is often severe neurotoxicity, and relapse remains frequent. Now a team of French researchers reports a preclinical result that could reshape how radiation is paired with one of modern medicine’s most powerful immune therapies: when they replaced conventional irradiation with a spatially fractionated technique called minibeam radiation therapy, the combination with CD19-directed CAR T cells produced the longest survival yet seen in their rat model of the disease.

The study, published in the journal iScience, is the first preclinical evaluation of minibeam radiation therapy combined with CAR T cell therapy in an orthotopic model of primary CNS lymphoma. The researchers, working at Institut Curie and collaborating institutions, implanted luciferase-labeled human lymphoma cells into the caudate nucleus of immunodeficient RRGS rats, which carry human SIRPα and can accept human tumor and immune cells. Seven days after implantation, once bioluminescence imaging confirmed tumor establishment, the animals received either conventional radiotherapy or minibeam radiation therapy, and CAR T cells were infused intravenously either three or five days later.

The technical distinction between the two radiation modalities lies at the heart of the finding. Conventional radiotherapy delivers a uniform field of radiation across the target volume. Minibeam radiation therapy instead splits the dose into an array of narrowly collimated beams, in this case 700 micrometers wide with a center-to-center spacing of about 1.4 millimeters, producing a striking peak-and-valley dose landscape. At a mean dose of 30 Gy, the peak regions received roughly 83 Gy while the valleys received only about 4.5 Gy. This spatial modulation allows tumor cells to be effectively irradiated while normal tissue, which benefits from the low-dose valleys and the ability of healthy cells to migrate in and repair, is largely spared.

That difference in physics translated into a difference in biology. Earlier work by the same group and others had shown that minibeam irradiation, unlike conventional radiotherapy, increases intratumoral CD8-positive tissue-resident memory T cells, B cells, and type 1 conventional dendritic cells, while conventional beams tend to promote immunosuppressive signaling. Because CAR T cell therapy depends on a permissive immune microenvironment, the researchers hypothesized that the choice of radiation modality could determine whether bridging radiotherapy helps or hinders the cellular therapy.

The survival data bore this out. In the definitive six-arm experiment, untreated animals survived a median of just 18 days. CAR T cell monotherapy at a dose of 5 million cells extended median survival to 43 days, with long-term survivors beyond 90 days in about a third of that group. Minibeam radiation alone at 30 Gy produced a median survival of 36 days, statistically indistinguishable from conventional radiotherapy alone at 32 days. But when minibeam was combined with CAR T cells infused five days after irradiation, median survival jumped to 83 days, the longest of any irradiated group, and a quarter of those animals survived long term. By contrast, adding CAR T cells to conventional radiotherapy yielded a median survival of only 37 days, essentially no better than conventional radiotherapy by itself.

The authors are careful about what this does and does not mean. Because the minibeam-plus-CAR T combination did not significantly outperform CAR T monotherapy, the data do not demonstrate pharmacological synergy. What they do show, the researchers argue, is that minibeam radiation provides a permissive, non-antagonistic context that preserves CAR T efficacy, whereas conventional radiotherapy appears to blunt it. In a clinical landscape where bridging radiotherapy between leukapheresis and CAR T infusion is increasingly common, that distinction could matter enormously. Clinical intervals between radiation and CAR T infusion range from 2 to 38 days, and the new results suggest that the type of beam, not merely the dose or timing, may shape the outcome.

Histopathology reinforced the survival curves. At the study endpoint, only 37.5 percent of animals in the minibeam-plus-CAR T group had detectable residual tumor, the lowest rate of any group, compared with 100 percent of untreated and conventionally irradiated animals and 64.3 percent of those receiving CAR T alone. The residual lesions in minibeam-treated animals were structurally loose, with fewer vascular abnormalities, less inflammatory infiltration, and minimal neural damage. Conventional radiotherapy, in contrast, was associated with diffuse spread, more frequent cavitation, greater neuronal damage, and fibrotic scarring. Strikingly, the combination of conventional radiotherapy with CAR T cells was linked to extensive brain necrosis, suggesting that rapid tumor clearance can outpace normal tissue repair and worsen neurotoxicity.

Tolerability data added a further point in minibeam’s favor. Animals across all groups generally gained weight during follow-up, and no overt systemic toxicity was observed. Skin injuries, a common radiation side effect, were variable in the conventionally irradiated groups and required topical treatment, whereas only a handful of minibeam animals showed minor lesions attributed mainly to self-scratching. The authors caution, however, that the study did not include dedicated neurological, behavioral, or detailed normal-brain toxicity assessments, so the safety profile remains incomplete.

The timing question yielded a suggestive but not definitive answer. Infusing CAR T cells five days after minibeam irradiation produced a median survival of 83 days versus 35.5 days for the three-day interval, and residual tumor incidence fell from 87.5 percent to 37.5 percent with the longer delay, but the difference did not reach statistical significance. The researchers describe the five-day interval as a reasonable scheduling strategy that warrants further investigation rather than an established optimum.

Several limitations frame the conclusions. The model used immunodeficient rats, so endogenous immune contributions to minibeam’s effects could not be assessed. Only CD19 immunohistochemistry was used to track tumor, meaning reduced staining could reflect antigen loss or modulation rather than true tumor clearance. The CAR T product was predominantly CD4-positive with relatively few cytotoxic CD8 cells, and only male animals were studied. The study was also designed as a therapeutic proof of concept, not a mechanistic investigation, so questions of CAR T trafficking, persistence, and tumor microenvironment remodeling remain open. Even so, the work makes a compelling case that radiotherapy modality should be a deliberate design choice when combining radiation with adoptive cell therapies. With minibeam radiation therapy already advancing through a canine trial that reported pathological complete remission in 71 percent of de novo brain tumors and its first human treatments, the prospect of a radiation technology that debulks tumors without sabotaging the immune cells sent to finish the job is moving steadily closer to the clinic.

Subject of Research: Combining minibeam radiation therapy with CD19 CAR T cell therapy in a rat model of primary central nervous system lymphoma

Article Title: Minibeam radiation therapy supports CAR T therapy in a rat model of CNS lymphoma

Article References: Iturri, L., Potiron, S., Sun, L., Juchaux, M., Gilbert, C., Espenon, J., Anegon, I., Ménoret, S., Soussain, C., Amigorena, S., Alcantara, M., & Prezado, Y. (2026). Minibeam radiation therapy supports CAR T therapy in a rat model of CNS lymphoma. iScience, 29(11), Article 117827. https://doi.org/10.1016/j.isci.2026.117827

Image Credits: AI Generated

DOI: 10.1016/j.isci.2026.117827

Keywords: minibeam radiation therapy, CAR T cells, primary CNS lymphoma, radiotherapy, immunotherapy, CD19, brain tumor, preclinical study, spatially fractionated radiation, tumor microenvironment, neurotoxicity, iScience